Skip to main content

Ovarian Hyperstimulation Syndrome

Question for Department of Health

UIN HL2977, tabled on 19 November 2014

To ask Her Majesty’s Government what sanctions the Human Fertilisation and Embryology Authority (HFEA) imposes if women are exposed to risks of ovarian hyperstimulation syndrome (OHSS); to what extent the HFEA advises clinics to use "OHSS prevention" protocols; what information the HFEA collects regarding the identities and dosages of drugs that women are exposed to during in vitro fertilisation treatment; and, if such data are not collected, what is the reason for not doing so.

Answered on

3 December 2014

The Human Fertilisation and Embryology Authority (HFEA) has advised that it has nothing further to add to the answer given to the noble Lord on 18 November 2014 (Official Report, col. WA107) in respect of clinical and professional advice or the evidence required to predict the cohort of patients. The HFEA ensures that licensed clinics advise women about the possible side effects and risks both to the woman being treated and to any resulting child, including the risk of Ovarian Hyperstimulation Syndrome (OHSS). Clinics should also advise patients what to do if symptoms arise and should have an emergency contact number which patients can use at any time. Clinics are also required to report to the HFEA cases of OHSS which require a hospital admission and has a severity grading of severe or critical.

The HFEA has also advised that it regards the prevention and management of OHSS as primarily the responsibility of clinical practice and subject to professional guidelines. The HFEA does not regulate the administration of drugs and therefore does not collect such data.